Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38172631.
- Also identified by DOI 10.1038/s41591-023-02669-x and PMC identifier 10921848.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.
Medical subject headings
- Diabetes Mellitus, Type 2